Teva Pharmaceutical (TEVA) delivered a compelling performance in the third quarter, with financial results exceeding market expectations. The company reported quarterly revenue of $4.48 billion, a 3% increase compared to the same period last year. This growth was primarily driven by the strong performance of two core drugs: Austedo sales grew 38% year-over-year to $618 million, while Ajovy sales increased 19% to $168 million. In terms of profitability, the company’s non-GAAP net profit rose 14% to $910 million, or $0.78 per share. This performance significantly surpassed analysts’ expectations, as the market had anticipated revenue of $4.36 billion and earnings per share of $0.68.
Based on its current performance, Teva Pharmaceutical appropriately adjusted its full-year guidance for the 2025 fiscal year. The company lowered the upper end of its revenue forecast by $200 million, setting the new expected range at $16.8 billion to $17 billion. Notably, Teva maintained its full-year net profit guidance unchanged at $2.55 to $2.65 per share. Driven by the strong financial results, the company’s stock price surged nearly 21% on the day of the earnings release, far outperforming the S&P 500’s 0.4% gain, reflecting the market’s positive recognition of the company’s performance.
Billionaire Stanley Druckenmiller and his Duquesne Family Office have shown particular interest in Teva Pharmaceutical in their investment strategy. Over the past year, the fund accumulated nearly 16 million Teva shares, with a position value exceeding $267 million by the end of the second quarter, making it the largest increase in holdings during that period. This investment decision reflects Druckenmiller’s confidence in Teva’s future growth prospects. Meanwhile, UBS analyst Ashwani Verma maintained a “Buy” rating on Teva and raised the company’s 2030 revenue expectation from $6.3 billion to $6.6 billion, primarily based on the strong anticipated performance of its branded drug business.
As one of the world’s leading generic drug manufacturers, Teva is actively advancing its “Transformational Growth” strategy. The company’s core product portfolio includes Austedo for neurodegenerative diseases and Ajovy for migraine prevention, along with drugs for treating conditions such as cancer and asthma. In terms of R&D, the company currently has five new drugs in late-stage development, three of which are in Phase III clinical trials, and two in Phase II trials. These investigational drugs primarily target disease areas affecting tens of millions of patients, such as asthma, inflammatory bowel disease, and schizophrenia. According to the plan, Teva will begin submitting new drug applications to regulatory authorities starting at the end of this year, continuing through 2029.
From a valuation perspective, Teva’s current forward price-to-earnings ratio of less than 8x is not uncommon among large pharmaceutical companies. However, considering the company’s consistently growing branded drug business, robust late-stage R&D pipeline, and steadily advancing growth strategy, this valuation may not fully reflect its long-term growth potential. Analyst Verma expects that the pricing discounts for Teva’s core product, Austedo, under insurance plans will not reach the levels of market concern in the short term, providing additional support for earnings growth. Overall, with its solid product foundation, clear strategic planning, and steadily progressing R&D efforts, Teva demonstrates sustainable growth potential.
